Pharsight

1. Drug name - ABILIFY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Jun, 2024 (1 year, 8 months from now)
US7115587	OTSUKA	Aripiprazole complex formulation and method	Jul, 2024 (1 year, 9 months from now)
US7550445	OTSUKA	Aripiprazole complex formulation and method	Jul, 2024 (1 year, 9 months from now)
US8017615 (Pediatric)	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Dec, 2024 (2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. Drug name - ABILIFY MAINTENA KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722679	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (2 years from now)
US8030313	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (2 years from now)
US7807680	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

3. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Jun, 2024 (1 year, 8 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

4. Drug name - ABRAXANE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8314156 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 8 months from now)
US8138229 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 8 months from now)
US7923536 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 8 months from now)
US7820788	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Oct, 2024 (2 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of lung cancer; treatment of breast cancer; treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

5. Drug name - ACULAR LS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207215	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8377982	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8648107	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8946281	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8906950	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US9216167	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8541463	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 7 months from now)
US8541463 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (2 years from now)
US8207215 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (2 years from now)
US8377982 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (2 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain; A method of treating or preventing ocular pain and burning; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.4%	SOLUTION/DROPS;OPHTHALMIC	Prescription

6. Drug name - ACUVAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952	ALLERGAN	Compositions for delivery of therapeutics into the eyes and methods for making and using same	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.45%	SOLUTION/DROPS;OPHTHALMIC	Prescription

7. Drug name - ADASUVE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629	ALEXZA PHARMS	Self-contained heating unit and drug-supply unit employing same	May, 2024 (1 year, 7 months from now)
US8991387	ALEXZA PHARMS	Self-contained heating unit and drug-supply unit employing same	May, 2024 (1 year, 7 months from now)
US7458374	ALEXZA PHARMS	Method and apparatus for vaporizing a compound	Aug, 2024 (1 year, 10 months from now)
US7537009	ALEXZA PHARMS	Method of forming an aerosol for inhalation delivery	Oct, 2024 (2 years from now)

Drugs and Companies using LOXAPINE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
10MG	POWDER;INHALATION	Prescription

8. Drug name - AIRDUO DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 11 months from now)
US9987229	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

9. Drug name - ALDARA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159	BAUSCH	Treatment for basal cell carcinoma	Apr, 2024 (1 year, 6 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159 (Pediatric)	BAUSCH	Treatment for basal cell carcinoma	Oct, 2024 (2 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
5%	CREAM;TOPICAL	Prescription

10. Drug name - ALIQOPA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041	BAYER HEALTHCARE	Fused azole-pyrimidine derivatives	May, 2024 (1 year, 7 months from now)

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

11. Drug name - ALOXI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947724	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9066980	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US8729094	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9457020	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US8518981	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9439854	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US7947725	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US8598218	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9457021	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9125905	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US7960424	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US9173942	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US8598219	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (1 year, 4 months from now)
US8518981 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US7960424 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US7947725 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US7947724 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US8598218 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9173942 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9439854 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9457020 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US8729094 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US8598219 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9125905 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9457021 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)
US9066980 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	INJECTABLE;INTRAVENOUS	Discontinued
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	INJECTABLE;INTRAVENOUS	Discontinued

12. Drug name - ALPHAGAN P

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Mar, 2024 (1 year, 5 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.1%	SOLUTION/DROPS;OPHTHALMIC	Prescription

13. Drug name - ALTABAX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191	ALMIRALL	Process, salts, composition and use	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
1%	OINTMENT;TOPICAL	Prescription

14. Drug name - AMITIZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312	SUCAMPO PHARMA LLC	Method for treating abdominal discomfort	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
8MCG	CAPSULE;ORAL	Prescription
24MCG	CAPSULE;ORAL	Prescription

15. Drug name - ANJESO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463673	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (1 year, 4 months from now)
US10471067	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML)	SOLUTION;INTRAVENOUS	Prescription

16. Drug name - ARIKAYCE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137	INSMED INC	Sustained release of antiinfectives	Apr, 2024 (1 year, 6 months from now)
US9827317	INSMED INC	Sustained release of antiinfectives	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

17. Drug name - ARMONAIR DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

18. Drug name - ATRIPLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744181	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US8592397	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US8716264	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US9457036	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults

Dosage: TABLET;ORAL

Strength	Dosage	Availability
600MG;200MG;300MG	TABLET;ORAL	Prescription

19. Drug name - AURYXIA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8338642	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US9757416	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US9328133	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US7767851	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
CN1751056A	KERYX BIOPHARMS	Ferric Organic Compound, Its Preparation Method And Its Application	Feb, 2024 (1 year, 4 months from now)
CN100386336C	KERYX BIOPHARMS	Ferric Organic Compound, Its Preparation Method And Its Application	Feb, 2024 (1 year, 4 months from now)
IN244119B	KERYX BIOPHARMS	Ferric Organic Compounds, Uses Thereof And Methods Of Making Same	Feb, 2024 (1 year, 4 months from now)
IN200500944P3	KERYX BIOPHARMS	Ferric Organic Compounds, Uses Thereof And Methods Of Making Same	Feb, 2024 (1 year, 4 months from now)
EP1601680A4	KERYX BIOPHARMS	Ferric Organic Compounds, Uses Thereof And Methods Of Making Same	Feb, 2024 (1 year, 4 months from now)
EP1601680B8	KERYX BIOPHARMS	Methods Of Making Ferric Organic Compounds	Feb, 2024 (1 year, 4 months from now)
EP1601680A2	KERYX BIOPHARMS	Methods Of Making Ferric Organic Compounds	Feb, 2024 (1 year, 4 months from now)
EP1601680B1	KERYX BIOPHARMS	Methods Of Making Ferric Organic Compounds	Feb, 2024 (1 year, 4 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050316	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US8299298	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same	Feb, 2024 (1 year, 4 months from now)
US8609896	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US8754257	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US8754258	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US8901349	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)
US8846976	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using FERRIC CITRATE ingredient

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 210MG IRON	TABLET;ORAL	Prescription

20. Drug name - AUVI-Q

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (2 years from now)
US9833573	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8920377	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.1MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.15MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.3MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

21. Drug name - BOSULIF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376	PF PRISM CV	Substituted 3-cyanoquinolines	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 500MG BASE	TABLET;ORAL	Prescription

22. Drug name - BRILINTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276	ASTRAZENECA	Triazolo(4,5-D)pyrimidine compounds	Oct, 2024 (2 years from now)
EP1135391B1	ASTRAZENECA	Novel Triazolo(4,5-D)Pyrimidine Compounds	Dec, 2024 (2 years from now)
EP1135391A1	ASTRAZENECA	Novel Triazolo(4,5-D)Pyrimidine Compounds	Dec, 2024 (2 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription

23. Drug name - BYDUREON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 6 months from now)
US7563871	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 6 months from now)
US7563871 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (2 years from now)
US9238076 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (2 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

24. Drug name - BYDUREON BCISE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 6 months from now)
US7563871	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 6 months from now)
US9238076 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (2 years from now)
US7563871 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (2 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.85ML (2MG/0.85ML)	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

25. Drug name - CABOMETYX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284	EXELIXIS INC	C-met modulators and method of use	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of renal cell carcinoma; treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

26. Drug name - CHILDREN'S ADVIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 7 months from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
100MG/5ML	SUSPENSION;ORAL	Over the counter

27. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 7 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
1MG/5ML;100MG/5ML;15MG/5ML	SUSPENSION;ORAL	Over the counter

28. Drug name - CHLORAPREP ONE-STEP

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6991394	BECTON DICKINSON CO	Liquid applicator with a mechanism for fracturing multiple ampoules	Jan, 2024 (1 year, 4 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Treatment: NA

Dosage: SPONGE;TOPICAL

Strength	Dosage	Availability
2%;70% (3ML)	SPONGE;TOPICAL	Over the counter
2%;70% (10.5ML)	SPONGE;TOPICAL	Over the counter
2%;70% (26ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1.5ML)	SPONGE;TOPICAL	Over the counter

29. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7066916	SAGE PRODS	Disinfectant delivery system, and method of providing alcohol-free disinfection	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: Disinfection of patient skin prior to an invasive procedure

Dosage: CLOTH;TOPICAL

Strength	Dosage	Availability
2%	CLOTH;TOPICAL	Over the counter

30. Drug name - COMBIVENT RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.1MG BASE/INH;0.02MG/INH	SPRAY, METERED;INHALATION	Prescription

31. Drug name - COMPLERA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457036	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US9744181	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US8592397	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)
US8716264	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;EQ 25MG BASE;300MG	TABLET;ORAL	Prescription

32. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7462626	NALPROPION	Compositions for affecting weight loss	Jul, 2024 (1 year, 9 months from now)
US8815889	NALPROPION	Compositions and methods for increasing insulin sensitivity	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

33. Drug name - DALIRESP

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618142	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 5 months from now)
US8604064	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 5 months from now)
US8536206	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 5 months from now)

Drugs and Companies using ROFLUMILAST ingredient

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

Strength	Dosage	Availability
250MCG	TABLET;ORAL	Prescription
500MCG	TABLET;ORAL	Prescription

34. Drug name - DEXILANT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722084 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 6 months from now)
US8784885 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

35. Drug name - DEXILANT SOLUTAB

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	Discontinued

36. Drug name - DEXTENZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267	OCULAR THERAPEUTIX	Composite hydrogel drug delivery systems	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: NA

Dosage: INSERT;OPHTHALMIC

Strength	Dosage	Availability
0.4MG	INSERT;OPHTHALMIC	Prescription

37. Drug name - DIFFERIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181	GALDERMA LABS LP	Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: NA

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.3%	GEL;TOPICAL	Prescription

38. Drug name - DIFICID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551 (Pediatric)	CUBIST PHARMS LLC	18-membered macrocycles and analogs thereof	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription

39. Drug name - DIPRIVAN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010	FRESENIUS KABI USA	Propofol formulations with non-reactive container closures	Dec, 2024 (2 years from now)

Drugs and Companies using PROPOFOL ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
10MG/ML	INJECTABLE;INJECTION	Prescription

40. Drug name - DUAVEE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535	WYETH PHARMS	2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations	May, 2024 (1 year, 7 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Treatment: Prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE;0.45MG	TABLET;ORAL	Prescription

41. Drug name - DURYSTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related implants	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

Strength	Dosage	Availability
10MCG	IMPLANT;OPHTHALMIC	Prescription

42. Drug name - DUTREBIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;EQ 300MG BASE	TABLET;ORAL	Discontinued

43. Drug name - DYMISTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163723 (Pediatric)	MYLAN SPECIALITY LP	Combination of azelastine and steroids	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.137MG/SPRAY;0.05MG/SPRAY	SPRAY, METERED;NASAL	Prescription

44. Drug name - ENTRESTO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390 (Pediatric)	NOVARTIS PHARMS CORP	Methods of treatment and pharmaceutical composition	May, 2024 (1 year, 7 months from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
24MG;26MG	TABLET;ORAL	Prescription
49MG;51MG	TABLET;ORAL	Prescription
97MG;103MG	TABLET;ORAL	Prescription

45. Drug name - ENVARSUS XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586084	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8889186	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8623411	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8889185	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US7994214	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8591946	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US9763920	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8623410	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8617599	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US9757362	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US10548880	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US9161907	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)
US8486993	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using TACROLIMUS ingredient

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 0.75MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 4MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

46. Drug name - EPIDUO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202	GALDERMA LABS LP	Method for treatment of common acne	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.1%;2.5%	GEL;TOPICAL	Prescription

47. Drug name - EQUETRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253	VALIDUS PHARMS	Methods for the treatment of bipolar disorder using carbamazepine	May, 2024 (1 year, 7 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
300MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

48. Drug name - EVEKEO ODT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580	ARBOR PHARMS LLC	Taste-masked pharmaceutical compositions	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
2.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
10MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
20MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

49. Drug name - EVOCLIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747	MYLAN	Pharmaceutical foam	Jan, 2024 (1 year, 3 months from now)
US7141237	MYLAN	Pharmaceutical foam	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
1%	AEROSOL, FOAM;TOPICAL	Prescription

50. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (2 years from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

51. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (2 years from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

52. Drug name - EXSERVAN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167	MITSUBISHI HOLDINGS	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2024 (1 year, 4 months from now)
US8603514	MITSUBISHI HOLDINGS	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using RILUZOLE ingredient

Treatment: NA

Dosage: FILM;ORAL

Strength	Dosage	Availability
50MG	FILM;ORAL	Prescription

53. Drug name - FARXIGA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

54. Drug name - FENOGLIDE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173847	SALIX	Tablet comprising a fibrate	Oct, 2024 (2 years from now)
US8481078	SALIX	Solid dosage form comprising a fibrate	Oct, 2024 (2 years from now)
US8124125	SALIX	Solid dosage form comprising a fibrate	Oct, 2024 (2 years from now)
US7658944	SALIX	Solid dosage form comprising a fibrate	Dec, 2024 (2 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
40MG	TABLET;ORAL	Prescription
120MG	TABLET;ORAL	Prescription

55. Drug name - FENTORA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119158	CEPHALON	Effervescent oral fentanyl dosage form and methods of administering fentanyl	Dec, 2024 (2 years from now)
US8092832	CEPHALON	Generally linear effervescent oral fentanyl dosage form and methods of administering	Dec, 2024 (2 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

Strength	Dosage	Availability
EQ 0.1MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.2MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.3MG BASE	TABLET;BUCCAL, SUBLINGUAL	Discontinued
EQ 0.4MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.6MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.8MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription

56. Drug name - FINACEA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435498	LEO PHARMA AS	Penetrating pharmaceutical foam	Mar, 2024 (1 year, 5 months from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
15%	AEROSOL, FOAM;TOPICAL	Prescription

57. Drug name - FLONASE SENSIMIST ALLERGY RELIEF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862	GLAXOSMITHKLINE CONS	Fluid dispensing device	Nov, 2024 (2 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.0275MG/SPRAY	SPRAY, METERED;NASAL	Over the counter

58. Drug name - FOSRENOL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428	TAKEDA PHARMS USA	Stabilized lanthanum carbonate compositions	Aug, 2024 (1 year, 10 months from now)
US7465465	TAKEDA PHARMS USA	Pharmaceutical formulation comprising lanthanum compounds	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

Strength	Dosage	Availability
EQ 1GM BASE	TABLET, CHEWABLE;ORAL	Prescription
EQ 250MG BASE	TABLET, CHEWABLE;ORAL	Discontinued
EQ 500MG BASE	TABLET, CHEWABLE;ORAL	Prescription
EQ 750MG BASE	TABLET, CHEWABLE;ORAL	Prescription

59. Drug name - GIVLAARI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610	ALNYLAM PHARMS INC	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (1 year, 3 months from now)
US9708615	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US10273477	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
CN1835897B	ALNYLAM PHARMS INC	Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank	Aug, 2024 (1 year, 10 months from now)
CN1835897A	ALNYLAM PHARMS INC	Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank	Aug, 2024 (1 year, 10 months from now)
EP2216407B1	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978A2	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978B1	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978A4	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A3	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A2	ALNYLAM PHARMS INC	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1615611A4	ALNYLAM PHARMS INC	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611B1	ALNYLAM PHARMS INC	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611A2	ALNYLAM PHARMS INC	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1620544A4	ALNYLAM PHARMS INC	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544A2	ALNYLAM PHARMS INC	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544B1	ALNYLAM PHARMS INC	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1765074A2	ALNYLAM PHARMS INC	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1765074A4	ALNYLAM PHARMS INC	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1765074B1	ALNYLAM PHARMS INC	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1667944B1	ALNYLAM PHARMS INC	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1667944A1	ALNYLAM PHARMS INC	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1677822A2	ALNYLAM PHARMS INC	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822A4	ALNYLAM PHARMS INC	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822B1	ALNYLAM PHARMS INC	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

60. Drug name - GRALISE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7438927	ALMATICA	Methods of treatment using a gastric retained gabapentin dosage	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription

61. Drug name - HYCAMTIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645	NOVARTIS	Compound, corresponding compositions, preparation and/or treatment methods	Dec, 2024 (2 years from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 1MG BASE	CAPSULE;ORAL	Prescription

62. Drug name - ILEVRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295	NOVARTIS	Ophthalmic compositions containing a synergistic combination of two polymers	Jun, 2024 (1 year, 8 months from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.3%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

63. Drug name - INBRIJA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7182961	ACORDA	Particulate compositions for pulmonary delivery	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
42MG	POWDER;INHALATION	Prescription

64. Drug name - INJECTAFER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612109	AM REGENT	Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM IRON/20ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
750MG IRON/15ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG IRON/2ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG IRON/10ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription

65. Drug name - INVOKAMET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG;500MG	TABLET;ORAL	Prescription
50MG;1GM	TABLET;ORAL	Prescription
150MG;500MG	TABLET;ORAL	Prescription
150MG;1GM	TABLET;ORAL	Prescription

66. Drug name - INVOKAMET XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
50MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
150MG;500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

67. Drug name - IONSYS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902	THE MEDICINES CO	Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

Strength	Dosage	Availability
EQ 40MCG BASE/ACTIVATION	SYSTEM;IONTOPHORESIS, TRANSDERMAL	Discontinued

68. Drug name - ISENTRESS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

69. Drug name - IXEMPRA KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237	R-PHARM US LLC	Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using IXABEPILONE ingredient

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
15MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription
45MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription

70. Drug name - KOSELUGO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7425637	ASTRAZENECA	N3 alkylated benzimidazole derivatives as MEK inhibitors	Apr, 2024 (1 year, 6 months from now)
EP1663210A4	ASTRAZENECA	N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors	Aug, 2024 (1 year, 10 months from now)
EP1663210A1	ASTRAZENECA	Benzimidazole Derivatives As Mek Inhibitors	Aug, 2024 (1 year, 10 months from now)
EP1663210B1	ASTRAZENECA	Benzimidazole Derivatives As Mek Inhibitors	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using SELUMETINIB SULFATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 25MG BASE	CAPSULE;ORAL	Prescription

71. Drug name - KUVAN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433624	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (2 years from now)
US8067416	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (2 years from now)
US7566714	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (2 years from now)
USRE43797	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin	Nov, 2024 (2 years from now)
US7612073	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring	Nov, 2024 (2 years from now)
US8318745	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (2 years from now)
US7727987	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (2 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

72. Drug name - KYNMOBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167	SUNOVION PHARMS INC	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2024 (1 year, 4 months from now)
US8603514	SUNOVION PHARMS INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FILM;SUBLINGUAL

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

73. Drug name - LATISSE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161	ALLERGAN	Method of enhancing hair growth	May, 2024 (1 year, 7 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Method of stimulating hair growth; method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

Strength	Dosage	Availability
0.03%	SOLUTION/DROPS;TOPICAL	Prescription

74. Drug name - LATUDA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975	SUNOVION PHARMS INC	Remedy for integration dysfunction syndrome	Feb, 2024 (1 year, 4 months from now)
US9815827	SUNOVION PHARMS INC	Agent for treatment of schizophrenia	Feb, 2024 (1 year, 4 months from now)
US9174975 (Pediatric)	SUNOVION PHARMS INC	Remedy for integration dysfunction syndrome	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription
80MG	TABLET;ORAL	Prescription
120MG	TABLET;ORAL	Prescription

75. Drug name - LAZANDA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078814	BTCP PHARMA	Intranasal spray device containing pharmaceutical composition	Jan, 2024 (1 year, 3 months from now)
US9814705	BTCP PHARMA	Intranasal spray device containing pharmaceutical composition	Jan, 2024 (1 year, 3 months from now)
US8889176	BTCP PHARMA	Method of managing or treating pain	Jan, 2024 (1 year, 3 months from now)
US8216604	BTCP PHARMA	Method of managing or treating pain	Oct, 2024 (2 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
EQ 0.1MG BASE	SPRAY, METERED;NASAL	Prescription
EQ 0.3MG BASE	SPRAY, METERED;NASAL	Discontinued
EQ 0.4MG BASE	SPRAY, METERED;NASAL	Prescription

76. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610	NOVARTIS	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (1 year, 3 months from now)
US9708615	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US10273477	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
US10669544	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 5 months from now)
CN1835897B	NOVARTIS	Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank	Aug, 2024 (1 year, 10 months from now)
CN1835897A	NOVARTIS	Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank	Aug, 2024 (1 year, 10 months from now)
EP2216407B1	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978A2	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978B1	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1605978A4	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A3	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP2216407A2	NOVARTIS	Therapeutic Compositions	Mar, 2024 (1 year, 5 months from now)
EP1615611A4	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611B1	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1615611A2	NOVARTIS	Irna Conjugates	Apr, 2024 (1 year, 6 months from now)
EP1620544A4	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544A2	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1620544B1	NOVARTIS	Modified Irna Agents	Apr, 2024 (1 year, 6 months from now)
EP1765074A2	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1765074A4	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1765074B1	NOVARTIS	Positionally Modified Sirna Constructs	Jun, 2024 (1 year, 8 months from now)
EP1667944B1	NOVARTIS	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1667944A1	NOVARTIS	Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour	Aug, 2024 (1 year, 10 months from now)
EP1677822A2	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822A4	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)
EP1677822B1	NOVARTIS	4'-Thionucleosides And Oligomeric Compounds	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

77. Drug name - LINZESS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7704947	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (1 year, 3 months from now)
US8080526	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (1 year, 3 months from now)
US7745409	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (1 year, 3 months from now)
US7371727	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (1 year, 3 months from now)
CN101787073B	ALLERGAN	Methods And Compositions For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
CN101787073A	ALLERGAN	Method And Composition For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
CN1795007A	ALLERGAN	Method And Composition For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
CN100589839C	ALLERGAN	Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide	Jan, 2024 (1 year, 3 months from now)
IN200503394P1	ALLERGAN	Methods And Compositions For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
IN237521B	ALLERGAN	A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
EP1911763B1	ALLERGAN	Compositions For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
EP1911763A2	ALLERGAN	Compositions For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
EP1911763A3	ALLERGAN	Compositions For The Treatment Of Gastrointestinal Disorders	Jan, 2024 (1 year, 3 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
72MCG	CAPSULE;ORAL	Prescription
145MCG	CAPSULE;ORAL	Prescription
290MCG	CAPSULE;ORAL	Prescription

78. Drug name - LIVALO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993	KOWA CO	Crystalline forms of pitavastatin calcium	Feb, 2024 (1 year, 4 months from now)
US7022713	KOWA CO	Hyperlipemia therapeutic agent	Feb, 2024 (1 year, 4 months from now)
US8557993 (Pediatric)	KOWA CO	Crystalline forms of pitavastatin calcium	Aug, 2024 (1 year, 10 months from now)
US7022713 (Pediatric)	KOWA CO	Hyperlipemia therapeutic agent	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 2MG BASE	TABLET;ORAL	Prescription
EQ 4MG BASE	TABLET;ORAL	Prescription

79. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372	SUNOVION RESP	Inhalation therapy device	Nov, 2024 (2 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

80. Drug name - LYNPARZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7449464	ASTRAZENECA	Phthalazinone derivatives	Oct, 2024 (2 years from now)
US7981889	ASTRAZENECA	Phthalazinone derivatives	Oct, 2024 (2 years from now)
CN1788000B	ASTRAZENECA	Phthalazine Ketone Derivatives	Mar, 2024 (1 year, 5 months from now)
CN1788000A	ASTRAZENECA	Phthalazinone Derivatives	Mar, 2024 (1 year, 5 months from now)
CN102107008B	ASTRAZENECA	Dna Damage Repair Inhibitor For The Treatment Of Cancer	Mar, 2024 (1 year, 5 months from now)
CN102107008A	ASTRAZENECA	Dna Damage Repair Inhibitor For Treatment Of Cancer	Mar, 2024 (1 year, 5 months from now)
CN1905864B	ASTRAZENECA	For Dna Damage Repair Inhibitors For Treating Cancer	Mar, 2024 (1 year, 5 months from now)
CN1905864A	ASTRAZENECA	Dna Damage And Repair Inhibitor For Curing Cancer	Mar, 2024 (1 year, 5 months from now)
EP1684736A1	ASTRAZENECA	Dna Damage Repair Inhibitors For Treatment Of Cancer	Nov, 2024 (2 years from now)
EP2305221A1	ASTRAZENECA	Dna Damage Repair Inhibitors For Treatment Of Cancer	Nov, 2024 (2 years from now)
EP1684736B1	ASTRAZENECA	Dna Damage Repair Inhibitors For Treatment Of Cancer	Nov, 2024 (2 years from now)
EP2305221B1	ASTRAZENECA	Dna Damage Repair Inhibitors For Treatment Of Cancer	Nov, 2024 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 5 months from now)
US9169235	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 5 months from now)
US9566276	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 5 months from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued

81. Drug name - MAVENCLAD

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (1 year, 6 months from now)
US8785415	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using CLADRIBINE ingredient

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription

82. Drug name - MAYZENT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519	NOVARTIS	Immunosuppresant compounds and compositions	May, 2024 (1 year, 7 months from now)
CN1791395A	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
CN1791395B	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
IN234287B	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
IN200503060P4	NOVARTIS	Immunosuppresant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP2514743A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1628967A1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336A2	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP2514743B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1644367B1	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1638551A2	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)
EP1633336A4	NOVARTIS	Immunosuppressant Compounds And Compositions	May, 2024 (1 year, 7 months from now)

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 2MG BASE	TABLET;ORAL	Prescription

83. Drug name - MEGACE ES

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107827	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 6 months from now)
US9101540	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 6 months from now)
US7101576	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 6 months from now)
US9101549	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 6 months from now)
US9040088	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
125MG/ML	SUSPENSION;ORAL	Prescription

84. Drug name - METHYLIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880	SPECGX LLC	Methylphenidate solution and associated methods of administration and production	Oct, 2024 (2 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
5MG/5ML	SOLUTION;ORAL	Prescription
10MG/5ML	SOLUTION;ORAL	Prescription

85. Drug name - MIRVASO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551	GALDERMA LABS LP	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	May, 2024 (1 year, 7 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
EQ 0.33% BASE	GEL;TOPICAL	Prescription

86. Drug name - MOVANTIK

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500	REDHILL	Polymer conjugates of opioid antagonists	Jun, 2024 (1 year, 8 months from now)
US8067431	REDHILL	Chemically modified small molecules	Dec, 2024 (2 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE	TABLET;ORAL	Prescription

87. Drug name - MOVIPREP

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381	SALIX PHARMS	Colon cleansing compositions and methods	Sep, 2024 (1 year, 11 months from now)
US7658914	SALIX PHARMS	Colon cleansing compositions	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	FOR SOLUTION;ORAL	Prescription

88. Drug name - MULPLETA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746	SHIONOGI INC	Compounds exhibiting thrombopoietin receptor agonism	Sep, 2024 (1 year, 11 months from now)
CN103130739B	SHIONOGI INC	Compound With Thrombopoietin Receptor Agonist Action	Aug, 2024 (1 year, 10 months from now)
CN102796058B	SHIONOGI INC	Compound With Thrombopoietin Receptor Agonist Action	Aug, 2024 (1 year, 10 months from now)
CN103130739A	SHIONOGI INC	Compound With Thrombopoietin Receptor Agonist Action	Aug, 2024 (1 year, 10 months from now)
CN102796058A	SHIONOGI INC	Compound Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)
IN232700B	SHIONOGI INC	Compounds Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)
IN200600512P4	SHIONOGI INC	Compounds Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)
EP1655291B1	SHIONOGI INC	Compounds Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)
EP1655291A1	SHIONOGI INC	Compounds Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)
EP1655291A4	SHIONOGI INC	Compounds Having Thrombopoietin Receptor Agonism	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using LUSUTROMBOPAG ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription

89. Drug name - MYFEMBREE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Jan, 2024 (1 year, 3 months from now)
US8058280	MYOVANT SCIENCES	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan, 2024 (1 year, 3 months from now)
CN100360538C	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
CN1768065A	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
IN235678B	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
IN200501636P2	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446A4	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446A1	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446B1	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG;0.5MG;40MG	TABLET;ORAL	Prescription

90. Drug name - MYRBETRIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835474 (Pediatric)	APGDI	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient	May, 2024 (1 year, 7 months from now)
USRE44872 (Pediatric)	APGDI	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient	May, 2024 (1 year, 7 months from now)
US7342117 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 7 months from now)
US7982049 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 7 months from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

91. Drug name - MYRBETRIQ GRANULES

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 7 months from now)
US7342117 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 7 months from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
8MG/ML	FOR SUSPENSION, EXTENDED RELEASE;ORAL	Prescription

92. Drug name - NAROPIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8162915	FRESENIUS KABI USA	Connector for packings containing medical liquids, and corresponding packing for medical liquids	May, 2024 (1 year, 7 months from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INJECTION

Strength	Dosage	Availability
1GM/200ML (5MG/ML)	SOLUTION;INJECTION	Prescription
50MG/10ML (5MG/ML)	SOLUTION;INJECTION	Discontinued
20MG/10ML (2MG/ML)	SOLUTION;INJECTION	Prescription
40MG/20ML (2MG/ML)	SOLUTION;INJECTION	Prescription
75MG/10ML (7.5MG/ML)	SOLUTION;INJECTION	Discontinued
100MG/20ML (5MG/ML)	SOLUTION;INJECTION	Prescription
100MG/10ML (10MG/ML)	SOLUTION;INJECTION	Prescription
150MG/20ML (7.5MG/ML)	SOLUTION;INJECTION	Prescription
150MG/30ML (5MG/ML)	SOLUTION;INJECTION	Prescription
200MG/100ML (2MG/ML)	SOLUTION;INJECTION	Prescription
200MG/20ML (10MG/ML)	SOLUTION;INJECTION	Prescription
400MG/200ML (2MG/ML)	SOLUTION;INJECTION	Prescription
500MG/100ML (5MG/ML)	SOLUTION;INJECTION	Prescription

93. Drug name - NASCOBAL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Feb, 2024 (1 year, 4 months from now)
US7404489	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Mar, 2024 (1 year, 5 months from now)
US9415007	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Jul, 2024 (1 year, 9 months from now)
US8003353	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 10 months from now)
US7879349	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 10 months from now)
US7229636	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.5MG/SPRAY	SPRAY, METERED;NASAL	Prescription

94. Drug name - NATESTO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784882	ACERUS	Controlled release delivery system for nasal applications and method of treatment	Feb, 2024 (1 year, 4 months from now)
US8784869	ACERUS	Controlled release delivery system for nasal applications and methods of treatment	Feb, 2024 (1 year, 4 months from now)
US8574622	ACERUS	Controlled release delivery system for nasal applications	Feb, 2024 (1 year, 4 months from now)
US8877230	ACERUS	Controlled release delivery system for nasal applications	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

Strength	Dosage	Availability
5.5MG/0.122GM ACTUATION	GEL, METERED;NASAL	Prescription

95. Drug name - NINLARO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608	TAKEDA PHARMS USA	Proteasome inhibitors and methods of using the same	Aug, 2024 (1 year, 10 months from now)
CN1867572A	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Use Thereof	Aug, 2024 (1 year, 10 months from now)
CN1867572B	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Use Thereof	Aug, 2024 (1 year, 10 months from now)
IN200600565P2	TAKEDA PHARMS USA	Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation	Aug, 2024 (1 year, 10 months from now)
IN231455B	TAKEDA PHARMS USA	Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation .	Aug, 2024 (1 year, 10 months from now)
EP1660507B2	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Using The Same	Aug, 2024 (1 year, 10 months from now)
EP1660507B1	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Using The Same	Aug, 2024 (1 year, 10 months from now)
EP1660507B9	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Using The Same	Aug, 2024 (1 year, 10 months from now)
EP1660507A2	TAKEDA PHARMS USA	Proteasome Inhibitors And Methods Of Using The Same	Aug, 2024 (1 year, 10 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115	TAKEDA PHARMS USA	Proteasome inhibitors and methods of using the same	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 2.3MG BASE	CAPSULE;ORAL	Prescription
EQ 3MG BASE	CAPSULE;ORAL	Prescription
EQ 4MG BASE	CAPSULE;ORAL	Prescription

96. Drug name - NOCDURNA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560429	FERRING PHARMS INC	Orodispersible dosage forms of desmopressin acetate	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
0.0277MG	TABLET;SUBLINGUAL	Prescription
0.0553MG	TABLET;SUBLINGUAL	Prescription

97. Drug name - NOCTIVA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799761	SERENITY PHARMS LLC	Pharmaceutical compositions including low dosages of desmopressin	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.00083MG/SPRAY	SPRAY, METERED;NASAL	Discontinued
0.00166MG/SPRAY	SPRAY, METERED;NASAL	Discontinued

98. Drug name - NOURIANZ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363	KYOWA KIRIN	Microcrystal	Nov, 2024 (2 years from now)
CN1784405A	KYOWA KIRIN	Microcrystalline	May, 2024 (1 year, 7 months from now)
CN100395245C	KYOWA KIRIN	Microcrystalline	May, 2024 (1 year, 7 months from now)
EP1626049A1	KYOWA KIRIN	Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione	May, 2024 (1 year, 7 months from now)
EP1626049A4	KYOWA KIRIN	Microcrystal	May, 2024 (1 year, 7 months from now)
EP1626049B1	KYOWA KIRIN	Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione	May, 2024 (1 year, 7 months from now)

Drugs and Companies using ISTRADEFYLLINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription

99. Drug name - NUCYNTA ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Oct, 2024 (2 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 250MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

100. Drug name - NUPLAZID

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618130	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (1 year, 3 months from now)
US9566271	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (1 year, 3 months from now)
US10028944	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (1 year, 3 months from now)
US8921393	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of psychosis or a symptom thereof; Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 34MG BASE	CAPSULE;ORAL	Prescription

101. Drug name - NUVIGIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 (Pediatric)	CEPHALON	Pharmaceutical formulations of modafinil	May, 2024 (1 year, 7 months from now)
US7132570 (Pediatric)	CEPHALON	Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil	Jun, 2024 (1 year, 8 months from now)

Drugs and Companies using ARMODAFINIL ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Discontinued
150MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription
250MG	TABLET;ORAL	Prescription

102. Drug name - NYMALIZE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8517997	ARBOR PHARMS LLC	Dispenser for medicaments and method and apparatus for making same	May, 2024 (1 year, 7 months from now)

Drugs and Companies using NIMODIPINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
3MG/ML	SOLUTION;ORAL	Discontinued
6MG/ML	SOLUTION;ORAL	Prescription

103. Drug name - OFEV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093	BOEHRINGER INGELHEIM	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription
EQ 150MG BASE	CAPSULE;ORAL	Prescription

104. Drug name - OMEGAVEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186	FRESENIUS KABI USA	Treatment and prevention of liver disease associated with parenteral nutrition (PN)	Nov, 2024 (2 years from now)

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

Strength	Dosage	Availability
5GM/50ML (0.1GM/ML)	EMULSION;INTRAVENOUS	Prescription
10GM/100ML (0.1GM/ML)	EMULSION;INTRAVENOUS	Prescription

105. Drug name - OMIDRIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173707 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (1 year, 4 months from now)
US8586633 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (1 year, 4 months from now)
US9278101 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (1 year, 4 months from now)
US9399040 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (1 year, 4 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;IRRIGATION

Strength	Dosage	Availability
EQ 0.3% BASE;EQ 1% BASE	SOLUTION;IRRIGATION	Prescription

106. Drug name - OMONTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 7 months from now)
US7919118	TAKEDA PHARMS USA	Spacer moiety for poly (ethylene glycol) modified peptide based compounds	May, 2024 (1 year, 7 months from now)
US7528104	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 7 months from now)
US7414105	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 7 months from now)
IN200502499P2	TAKEDA PHARMS USA	A Peptide Dimer	May, 2024 (1 year, 7 months from now)
IN224732B	TAKEDA PHARMS USA	A Peptide Dimer	May, 2024 (1 year, 7 months from now)
IN200502493P2	TAKEDA PHARMS USA	A Peptide Cross-Reference To Related Applications	May, 2024 (1 year, 7 months from now)
IN228387B	TAKEDA PHARMS USA	A Peptide	May, 2024 (1 year, 7 months from now)
EP1629007B1	TAKEDA PHARMS USA	Novel Peptides That Bind To The Erythropoietin Receptor	May, 2024 (1 year, 7 months from now)
EP1625156B1	TAKEDA PHARMS USA	Peptides That Bind To The Erythropoietin Receptor	May, 2024 (1 year, 7 months from now)
EP1629007A2	TAKEDA PHARMS USA	Novel Peptides That Bind To The Erythropoietin Receptor	May, 2024 (1 year, 7 months from now)
EP1625156A2	TAKEDA PHARMS USA	Peptides That Bind To The Erythropoietin Receptor	May, 2024 (1 year, 7 months from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	Discontinued

107. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119932	CURRAX	Nasal delivery device	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: NA

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

108. Drug name - OPANA ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383	ENDO PHARMS	Abuse-proofed dosage form	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
7.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
20MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
40MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

109. Drug name - ORACEA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709478	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 6 months from now)
US8470364	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 6 months from now)
US8394405	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 6 months from now)
US8394406	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
40MG	CAPSULE;ORAL	Prescription

110. Drug name - ORENITRAM

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 7 months from now)
CN101265226A	UNITED THERAP	Compound And Method For Delivery Of Prostacyclin Analogueue	May, 2024 (1 year, 7 months from now)
CN101780092B	UNITED THERAP	Compounds And Method For Releasing Prostacyclin Analogue	May, 2024 (1 year, 7 months from now)
CN100558351C	UNITED THERAP	Composition And Method For Releasing Prostacyclin Analogue	May, 2024 (1 year, 7 months from now)
CN101265226B	UNITED THERAP	Composition And Method For Releasing Prostacyclin Analogue	May, 2024 (1 year, 7 months from now)
CN101780092A	UNITED THERAP	Compound And Method For Releasing Prostacyclin Analogue	May, 2024 (1 year, 7 months from now)
CN1822826A	UNITED THERAP	Compounds And Method For Releasing Prostacyclin Analogue	May, 2024 (1 year, 7 months from now)
IN200502621P2	UNITED THERAP	An Oral Pharmaceutical Composition	May, 2024 (1 year, 7 months from now)
IN247151B	UNITED THERAP	An Oral Pharmaceutical Composition	May, 2024 (1 year, 7 months from now)
EP1628654B1	UNITED THERAP	Compounds And Methods For Delivery Of Prostacyclin Analogs	May, 2024 (1 year, 7 months from now)
EP1628654A4	UNITED THERAP	Compounds And Methods For Delivery Of Prostacyclin Analogs	May, 2024 (1 year, 7 months from now)
EP2792353A3	UNITED THERAP	Compounds And Methods For Delivery Of Prostacyclin Analogs	May, 2024 (1 year, 7 months from now)
EP1628654A2	UNITED THERAP	Compounds And Methods For Delivery Of Prostacyclin Analogs	May, 2024 (1 year, 7 months from now)
EP2792353B1	UNITED THERAP	Polymorph Of Treprostinil Diethanolamine Salt	May, 2024 (1 year, 7 months from now)
EP2792353A2	UNITED THERAP	Polymorph Of Treprostinil Diethanolamine Salt	May, 2024 (1 year, 7 months from now)
EP1628654B2	UNITED THERAP	Compounds And Methods For Delivery Of Prostacyclin Analogs	May, 2024 (1 year, 7 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9422223	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 7 months from now)
US9278901	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 7 months from now)
US8252839	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 7 months from now)
US7544713	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 0.125MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 0.25MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

111. Drug name - ORGOVYX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280	MYOVANT SCIENCES	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan, 2024 (1 year, 3 months from now)
US7300935	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Jan, 2024 (1 year, 3 months from now)
CN100360538C	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
CN1768065A	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
IN235678B	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
IN200501636P2	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446A4	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446A1	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
EP1591446B1	MYOVANT SCIENCES	Thienopyrimidine Compounds And Use Thereof	Jan, 2024 (1 year, 3 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using RELUGOLIX ingredient

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent

Dosage: TABLET;ORAL

Strength	Dosage	Availability
120MG	TABLET;ORAL	Prescription

112. Drug name - ORIAHNN (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 9 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 11 months from now)
CN100424078C	ABBVIE INC	As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives	Jul, 2024 (1 year, 9 months from now)
CN1819829A	ABBVIE INC	As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives	Jul, 2024 (1 year, 9 months from now)
IN200600072P1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
IN312234B	ABBVIE INC	Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
EP1646389A1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
EP1646389B1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	CAPSULE;ORAL	Prescription

113. Drug name - ORILISSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 9 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 11 months from now)
CN100424078C	ABBVIE INC	As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives	Jul, 2024 (1 year, 9 months from now)
CN1819829A	ABBVIE INC	As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives	Jul, 2024 (1 year, 9 months from now)
IN200600072P1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
IN312234B	ABBVIE INC	Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
EP1646389A1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
EP1646389B1	ABBVIE INC	Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists	Jul, 2024 (1 year, 9 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Jul, 2024 (1 year, 9 months from now)

Drugs and Companies using ELAGOLIX SODIUM ingredient

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

114. Drug name - OSPHENA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470890	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 4 months from now)
US9241915	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 4 months from now)
US9855224	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 4 months from now)
US8772353	DUCHESNAY	Method for enhancing the bioavalability of ospemifene	Feb, 2024 (1 year, 4 months from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

115. Drug name - OXAYDO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492443	ZYLA	Abuse deterrent compositions and methods of making same	May, 2024 (1 year, 7 months from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
7.5MG	TABLET;ORAL	Prescription

116. Drug name - OZEMPIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (1 year, 7 months from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/1.5ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
4MG/3ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

117. Drug name - PONVORY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728	JANSSEN PHARMS	Thiazolidin-4-one derivatives	Nov, 2024 (2 years from now)
IN254201B	JANSSEN PHARMS	Novel Thiazolidin-4-One Derivatives	Nov, 2024 (2 years from now)
IN200602225P4	JANSSEN PHARMS	Novel Thiazoldin-4-One Derivatives	Nov, 2024 (2 years from now)
EP1689726A1	JANSSEN PHARMS	5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents	Nov, 2024 (2 years from now)
EP1689726B1	JANSSEN PHARMS	5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents	Nov, 2024 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018	JANSSEN PHARMS	Thiazolidin-4-one-derivatives	Nov, 2024 (2 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

118. Drug name - PREVYMIS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791	MERCK SHARP DOHME	Substituted dihydroquinazolines	May, 2024 (1 year, 7 months from now)
US8513255	MERCK SHARP DOHME	Substituted dihydroquinazolines	May, 2024 (1 year, 7 months from now)
CN100393706C	MERCK SHARP DOHME	Substituted Dihydroquinazolin Having Anti-Virus Capability	Apr, 2024 (1 year, 6 months from now)
CN1784390A	MERCK SHARP DOHME	Substituted Dihydroquinazolin Having Anti-Virus Capability	Apr, 2024 (1 year, 6 months from now)
IN200504403P1	MERCK SHARP DOHME	Substituted Dihydroquinazolines	Apr, 2024 (1 year, 6 months from now)
IN230768B	MERCK SHARP DOHME	Substituted Dihydroquinazoline Compounds	Apr, 2024 (1 year, 6 months from now)
EP1622880B3	MERCK SHARP DOHME	Substituted Dihydrochinazolines Having Antiviral Properties	Apr, 2024 (1 year, 6 months from now)
EP1622880A1	MERCK SHARP DOHME	Substituted Dihydrochinazolines Having Antiviral Properties	Apr, 2024 (1 year, 6 months from now)
EP1622880B1	MERCK SHARP DOHME	Substituted Dihydrochinazolines Having Antiviral Properties	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using LETERMOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
240MG/12ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription
480MG/24ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription

119. Drug name - PREZCOBIX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Feb, 2024 (1 year, 4 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;800MG	TABLET;ORAL	Prescription

120. Drug name - PREZISTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Feb, 2024 (1 year, 4 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using DARUNAVIR ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
100MG/ML	SUSPENSION;ORAL	Prescription

121. Drug name - PRIALT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765680	TERSERA	Method for administering omega-conopeptide	Oct, 2024 (2 years from now)
US8653033	TERSERA	Method for administering omega-conopeptide	Oct, 2024 (2 years from now)
US9707270	TERSERA	Method for administering ω-conopeptide	Oct, 2024 (2 years from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Treatment: Treatment of pain; analgesia; Analgesia; treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

Strength	Dosage	Availability
100MCG/1ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Prescription
200MCG/2ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Discontinued
500MCG/20ML (25MCG/ML)	INJECTABLE;INTRATHECAL	Prescription
500MCG/5ML (100MCG/ML)	INJECTABLE;INTRATHECAL	Prescription

122. Drug name - PROBUPHINE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665	TITAN PHARMS	Implantable polymeric device for sustained release of buprenorphine	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: For opioid dependence

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
EQ 80MG BASE/IMPLANT	IMPLANT;IMPLANTATION	Discontinued

123. Drug name - PROLENSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871813	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)
US8754131	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)
US8669290	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)
US9144609	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)
US8927606	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)
US9561277	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (1 year, 3 months from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Method of treating ocular inflammation; method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.07% ACID	SOLUTION/DROPS;OPHTHALMIC	Prescription

124. Drug name - PROTONIX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7553498	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (2 years from now)
US7550153	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (2 years from now)
US7838027	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (2 years from now)

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription

125. Drug name - PROVIGIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 (Pediatric)	CEPHALON	Pharmaceutical formulations of modafinil	May, 2024 (1 year, 7 months from now)

Drugs and Companies using MODAFINIL ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

126. Drug name - RAYOS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309124	HORIZON	Delayed release tablet with defined core geometry	Apr, 2024 (1 year, 6 months from now)
US9186332	HORIZON	Delayed release tablet with defined core geometry	Apr, 2024 (1 year, 6 months from now)
US9040085	HORIZON	Delayed release tablet with defined core geometry	Apr, 2024 (1 year, 6 months from now)
US8394407	HORIZON	Delayed release tablet with defined core geometry	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using PREDNISONE ingredient

Treatment: Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
1MG	TABLET, DELAYED RELEASE;ORAL	Prescription
2MG	TABLET, DELAYED RELEASE;ORAL	Prescription
5MG	TABLET, DELAYED RELEASE;ORAL	Prescription

127. Drug name - RELISTOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025	SALIX PHARMS	Stable methylnaltrexone preparation	Apr, 2024 (1 year, 6 months from now)
US9669096	SALIX PHARMS	Stable pharmaceutical formulations of methylnaltrexone	Apr, 2024 (1 year, 6 months from now)
US10376584	SALIX PHARMS	Stable pharmaceutical formulations of methylnaltrexone	Apr, 2024 (1 year, 6 months from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
8MG/0.4ML (8MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
12MG/0.6ML (12MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Prescription

128. Drug name - REMODULIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 7 months from now)
US9713599	UNITED THERAP	Parenteral formulations of treprostinil	Dec, 2024 (2 years from now)
US10076505	UNITED THERAP	Inhalation formulations of Treprostinil	Dec, 2024 (2 years from now)
US10695308	UNITED THERAP	Inhalation formulations of treprostinil	Dec, 2024 (2 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

Strength	Dosage	Availability
1MG/ML	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	Prescription
2.5MG/ML	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	Prescription
5MG/ML	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	Prescription
10MG/ML	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	Prescription
20MG/ML	INJECTABLE;IV (INFUSION), SUBCUTANEOUS	Prescription

129. Drug name - RESTASIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642556	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8629111	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8633162	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8648048	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US8685930	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)
US9248191	ALLERGAN	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (1 year, 10 months from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

130. Drug name - REVLIMID

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855217	CELGENE	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Nov, 2024 (2 years from now)
EP2426118A1	CELGENE	Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione	Sep, 2024 (1 year, 11 months from now)
EP3045176B8	CELGENE	Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione	Sep, 2024 (1 year, 11 months from now)
EP2426118B1	CELGENE	Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione	Sep, 2024 (1 year, 11 months from now)
EP3045176A1	CELGENE	Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione	Sep, 2024 (1 year, 11 months from now)
EP3045176B1	CELGENE	Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione	Sep, 2024 (1 year, 11 months from now)

Drugs and Companies using LENALIDOMIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
2.5MG	CAPSULE;ORAL	Prescription
5MG	CAPSULE;ORAL	Prescription
10MG	CAPSULE;ORAL	Prescription
15MG	CAPSULE;ORAL	Prescription
20MG	CAPSULE;ORAL	Prescription
25MG	CAPSULE;ORAL	Prescription

131. Drug name - RHOFADE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929	EPI HLTH	Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists

Pharsight

Drug Patents Expiring in 2024

1. Drug name - ABILIFY

2. Drug name - ABILIFY MAINTENA KIT

3. Drug name - ABILIFY MYCITE KIT

4. Drug name - ABRAXANE

5. Drug name - ACULAR LS

6. Drug name - ACUVAIL

7. Drug name - ADASUVE

8. Drug name - AIRDUO DIGIHALER

9. Drug name - ALDARA

10. Drug name - ALIQOPA

11. Drug name - ALOXI

12. Drug name - ALPHAGAN P

13. Drug name - ALTABAX

14. Drug name - AMITIZA

15. Drug name - ANJESO

16. Drug name - ARIKAYCE KIT

17. Drug name - ARMONAIR DIGIHALER

18. Drug name - ATRIPLA

19. Drug name - AURYXIA

20. Drug name - AUVI-Q

21. Drug name - BOSULIF

22. Drug name - BRILINTA

23. Drug name - BYDUREON

24. Drug name - BYDUREON BCISE

25. Drug name - CABOMETYX

26. Drug name - CHILDREN'S ADVIL

27. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

28. Drug name - CHLORAPREP ONE-STEP

29. Drug name - CHLORHEXIDINE GLUCONATE

30. Drug name - COMBIVENT RESPIMAT

31. Drug name - COMPLERA

32. Drug name - CONTRAVE

33. Drug name - DALIRESP

34. Drug name - DEXILANT

35. Drug name - DEXILANT SOLUTAB

36. Drug name - DEXTENZA

37. Drug name - DIFFERIN

38. Drug name - DIFICID

39. Drug name - DIPRIVAN

40. Drug name - DUAVEE

41. Drug name - DURYSTA

42. Drug name - DUTREBIS

43. Drug name - DYMISTA

44. Drug name - ENTRESTO

45. Drug name - ENVARSUS XR

46. Drug name - EPIDUO

47. Drug name - EQUETRO

48. Drug name - EVEKEO ODT

49. Drug name - EVOCLIN

50. Drug name - EVZIO

51. Drug name - EVZIO (AUTOINJECTOR)

52. Drug name - EXSERVAN

53. Drug name - FARXIGA

54. Drug name - FENOGLIDE

55. Drug name - FENTORA

56. Drug name - FINACEA

57. Drug name - FLONASE SENSIMIST ALLERGY RELIEF

58. Drug name - FOSRENOL

59. Drug name - GIVLAARI

60. Drug name - GRALISE

61. Drug name - HYCAMTIN

62. Drug name - ILEVRO

63. Drug name - INBRIJA

64. Drug name - INJECTAFER

65. Drug name - INVOKAMET

66. Drug name - INVOKAMET XR

67. Drug name - IONSYS

68. Drug name - ISENTRESS

69. Drug name - IXEMPRA KIT

70. Drug name - KOSELUGO

71. Drug name - KUVAN

72. Drug name - KYNMOBI

73. Drug name - LATISSE

74. Drug name - LATUDA

75. Drug name - LAZANDA

76. Drug name - LEQVIO

77. Drug name - LINZESS

78. Drug name - LIVALO